MECHELEN, BELGIUM--(Marketwire - September 02, 2012) - Galapagos NV (Euronext: GLPG) announced
today that its service division BioFocus and Ono Pharmaceutical Co., Ltd.
Japan) have signed a new collaboration agreement, focused on discovering
drugs in the field of CNS disorders. Under the new agreement, BioFocus
its drug discovery platform to deliver leads and clinical candidates
client. Financial details were undisclosed.
"We are delighted to have this new agreement, which is the first drug
program with this, a most valued, client" said Dr. Chris Newton, SVP
Services and Managing Director of BioFocus. "This project plays to
historic strengths and the expanding breadth and depth of this
testament to a tried and trusted relationship."
Kazuhito Kawabata, Ph.D., Member of the Board of Directors, Executive
and Executive Director, Discovery and Research of Ono commented: "We
highest regard for the BioFocus' comprehensive drug discovery platform.
collaboration will strengthen Ono's drug discovery capability in the
CNS disorders with significant unmet medical needs and we are expecting
innovative drugs will be created through this collaboration."
BioFocus provides integrated drug discovery that delivers pre-clinical
candidates in all therapeutic areas with strong capability in
diseases, inflammatory diseases and with a growing track record of
candidates against rare and neglected diseases. BioFocus has
comprehensive drug discovery capabilities that are applied to client
deliver targets, hits, leads and candidate pre-clinical drugs. The
employs over 250 exceptionally qualified and industry experienced
its three research centers in the UK, Switzerland and the Netherlands.
its foundation in 1997, BioFocus has striven to produce high quality
its clients and this quality is assured by ISO9001 qualification
regular, independent inspection of all BioFocus research centers. For
information please visit www.biofocus.com.
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size clinical
biotechnology company specialized in the discovery and development of
molecule and antibody therapies with novel modes-of-action. The
progressing its JAK1 inhibitor GLPG0634, as well as one of the largest
in biotech, with four programs in development and over 30 discovery
The Galapagos Group has about 800 employees and operates facilities
countries, with global headquarters in Mechelen, Belgium. More
In keeping with its philosophy of "Dedicated to Man's Fight against
Pain," Ono has always striven to achieve its goal of serving as an R&D-
global specialty pharmaceuticals, aiming to develop innovative and
recognized drugs. To do this, Ono has been engaged in drug discovery
based on accumulated technologies and know-how - in areas where its
can be fully exploited (i.e. bioactive lipid agonists and enzyme inhibitors
as proteases and kinases). In addition, modulators of membrane
systems such as ion-channels and transporters as well as biotechnology-
medicines are also the areas of our focus where we drive forward our
effectively deploying our know-how from neuroscience research and our
assets together with the latest information acquired from global
institutions on drug discovery targets and the cutting-edge drug
technologies that biopharmaceutical companies can offer. For more
please visit www.ono.co.jp.
This release may contain forward-looking statements, including,
limitation, statements containing the words "believes,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"stands to," and "continues," as well as similar expressions. Such
looking statements may involve known and unknown risks, uncertainties and
factors which might cause the actual results, financial condition,
or achievements of Galapagos, or industry results, to be materially
from any historic or future results, financial conditions,
achievements expressed or implied by such forward-looking statements.
these uncertainties, the reader is advised not to place any undue
such forward-looking statements. These forward-looking statements speak
of the date of publication of this document. Galapagos expressly
obligation to update any such forward-looking statements in this
reflect any change in its expectations with regard thereto or any
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
BioFocus(®) is a trademark of Galapagos NV and/or its affiliates
2012 Galapagos NV.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE